JenKem Technology Co., Ltd.
Quick facts
Phase 3 pipeline
- JK-1201I · Endocrinology/Metabolic Disease
JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: